Clinical
RSSArticles
Nitrous Oxide-Induced Neuropathy
Nitrous oxide-induced neuropathy presents with a rapidly progressive sensorimotor neuropathy that may mimic Guillain-Barré syndrome. The pattern of clinical weakness and progression, as well as electrophysiological features, can help to rapidly distinguish the two disorders.
Comparison of the Efficacy of Rituximab vs. Ocrelizumab in the Treatment of Relapsing Multiple Sclerosis
Rituximab is an anti-CD20 chimeric monoclonal antibody used off-label to treat multiple sclerosis (MS). Ocrelizumab is a humanized monoclonal anti-CD20 monoclonal antibody that is Food and Drug Administration-approved for the treatment of MS. In this observational cohort study, the authors were not able to demonstrate noninferiority of rituximab compared to ocrelizumab because of a significantly lower relapse rate in the ocrelizumab-treated group.
Statins Might Lower Risk of Recurrent Stroke
Patients in Denmark who suffered an intracerebral hemorrhage and were taking cholesterol-lowering medication were less likely to experience another stroke.
Preventing and Reversing Cardiovascular Disease Through Lifestyle Modification
Cardiovascular disease (CVD) is the leading cause of death globally and in the United States. Identifying and targeting cardiovascular risk factors is essential for the prevention and long-term management of CVD. Traditionally, factors for the onset and progression of CVD were thought to be mostly genetic. It is now well established that several of these factors are lifestyle mediated. Behavioral changes significantly influence the interplay between a healthy lifestyle and the genetic risk of heart disease. To further understand the challenges with preventing and reversing CVD, providers need to consider the alarming prevalence of risk factors among the U.S. population.
An RNA Shot for Hypertension?
One dose of a new RNA-based drug administered by subcutaneous injection, which blocks hepatic angiotensinogen production, resulted in sustained reductions in blood pressure in patients with hypertension for up to 24 weeks without any serious adverse effects.
Is the Combination of a GLP-1 Agonist and a SGLT2 Inhibitor Safe?
Adding a GLP-1 RA in a subgroup of type 2 diabetes patients on baseline SGLT2 inhibitor therapy revealed GLP-1 RA reduces major adverse cardiovascular event rates, regardless of baseline SGLT2 use.
The Hemodynamic Effects of an SGLT2 Inhibitor in Heart Failure with Preserved Ejection Fraction
The authors of a small, placebo-controlled study of 24 weeks of dapagliflozin therapy in patients with heart failure with preserved ejection fraction reported reductions in pulmonary capillary wedge pressure, which may explain the reductions in heart failure hospitalizations or cardiovascular death in larger randomized outcome trials.
High-Impact Clinical Trials from the European Society of Cardiology Congress 2023
The following is an overview of important cardiology research presented Aug. 25 through Aug. 28 in Amsterdam and online during the ESC Congress 2023.
Is Planned Complete Revascularization After Myocardial Infarction Wise for Older Patients?
Among patients at least age 75 years presenting with acute myocardial infarction and multivessel coronary disease, physiology-guided complete revascularization led to a lower risk of major adverse cardiovascular events at one year vs. culprit lesion-only percutaneous coronary intervention.
Supine Blood Pressure Readings May Reveal Hidden Health Risks
Measuring a patient’s blood pressure while he or she is lying down could help clinicians learn more about possible underlying heart problems.